Results 201 to 210 of about 24,853 (244)

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial. [PDF]

Dermatol Ther (Heidelb)
Wu C, Niu X, Wang X, Su J, Zhao H, Lin M, Yang C, Qin X, Guo S, Jiang C, Tang H, Yang H, Wu L, Zhu M, Wei A, Tao X, Zhang Y, Shu C, Liu J, Yang L, Qian Y, Zhang B, Zhang S, Xu J, Lu Y, Peng M, Luo S, Ma W, Jin H.   +28 more
europepmc   +1 more source

Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey. [PDF]

J Clin Med
Bakırtaş M, Berber İ, Hindilerden İY, Dal MS, İzmir Güner Ş, Uysal A, Ekinci Ö, Aslan Candır B, Eser B, Akpınar S, Biçim S, Yiğenoğlu TN, Ulaş T, Turgut B, Erkurt MA, Altuntaş F.   +15 more
europepmc   +1 more source

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review. [PDF]

Front Immunol
Yin HQ, Jin S, Fu Y, Zhu HL, Li XF.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ruxolitinib

Drugs, 2012
Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis. JAK 1 and 2 are implicated in the development of myelofibrosis, as well as other haematological malignancies.
Lily P H Yang, Yang Lily P H
exaly   +4 more sources

Ruxolitinib

Reactions Weekly, 2018
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2012, followed by the approval for the treatment of ...
Ajayi, Stefanie, Becker, Heiko, Reinhardt, Heike, Engelhardt, Monika, Zeiser, Robert, Bubnoff, Nikolas von, Wäsch, Ralph   +6 more
  +6 more sources

Ruxolitinib

Reactions Weekly, 2014
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality ...
Becker, Heiko, Engelhardt, Monika, Bubnoff, Nikolas von, Wäsch, Ralph   +3 more
openaire   +4 more sources

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.

New England Journal of Medicine, 2022
BACKGROUND Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo.
D. Rosmarin, T. Passeron, A. Pandya, P. Grimes, J. Harris, S. Desai, M. Lebwohl, M. Ruer-Mulard, J. Seneschal, A. Wolkerstorfer, D. Kornacki, K. Sun, K. Butler, K. Ezzedine   +13 more
semanticscholar   +1 more source

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.

Blood
Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD (cGVHD) remain of high importance.
Zachariah M DeFilipp, Haesook T. Kim, Laura W Knight, Suzanne O'Connor, Shilton E Dhaver, Meghan White, Bhagirathbhai R. Dholaria, Mark A Schroeder, S. Vasu, S. Abedin, Jooho Chung, A. El-Jawahri, M. Frigault, S. Mcafee, Richard A. Newcomb, Paul O’Donnell, T. Spitzer, Yi-Bin Chen, Gabriela S. Hobbs   +18 more
semanticscholar   +1 more source

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

Journal of Clinical Oncology
In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD).
R. Zeiser, Domenico Russo, R. Ram, Shahrukh K. Hashmi, R. Chakraverty, J. Middeke, M. Musso, Sebastian Giebel, A. Uzay, Peter Langmuir, N. Hamad, Karin Burock, M. Gowda, T. Stefanelli, Stephanie J. Lee, Takanori Teshima, F. Locatelli   +16 more
semanticscholar   +1 more source

Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome

Blood
Key Points • Ruxolitinib alleviates systemic inflammation and induces remission in refractory AOSD-MAS.• Ruxolitinib modulates neutrophil activation in MAS by broadly inhibiting JAK-STAT signaling.
Yuning Ma, Xia Chen, Mengyan Wang, Jianfen Meng, Dehao Zhu, Longfang Chen, Yu Xiao, Da Yi, Hui Shi, Honglei Liu, Xiaobing Cheng, Yutong Su, Junna Ye, Huihui Chi, Zhuochao Zhou, Tingting Liu, Chengde Yang, Jialin Teng, Yue Sun, Jinchao Jia, Qiong-yi Hu   +20 more
semanticscholar   +1 more source